Blog

GSK Pharma Q2 Review: A Closer Look at the Numbers GlaxoSmithKline Pharmaceuticals Ltd. recently reported its Q2 results, which showed a decline in revenue on a year-over-year (YoY) basis. This decline can be attributed to certain one-time events such as the GST transition and the fire incident at GSK Pharma’s contract manufacturing facility. Despite the […]

Piramal Finance Relists On Stock Exchanges At 12% Premium Piramal Finance, a wholly-owned subsidiary of Piramal Enterprises, has relisted on the stock exchanges at a 12% premium. The shares debuted at Rs 1,260 per share on the NSE, compared to the discovered price of Rs 1,124.20. As of 10:50 a.m., the shares were trading 17.59%

MAS Financial Q2 Review: Strong Growth Prospects Ahead MAS Financial Services Ltd. has reported its Q2 results, and Axis Securities has reiterated its ‘Buy’ call on the stock. The brokerage firm expects strong growth prospects for the company, driven by a robust distribution network and adequate capitalization. The stock currently trades at 1.7x FY27E BV,

Motilal Oswal Downgrades Updater Services To ‘Neutral’ Amid Guidance Cuts, Near-Term Headwinds Updater Services Ltd. recently reported its Q2 FY26 results, which fell short of expectations. The company’s revenue grew 7% year-over-year (YoY) to Rs 7.3 billion, below the estimated Rs 7.7 billion. The core Ebitda margin came in at 4.3%, down 130 basis points

Zydus Lifesciences Q2 Review: A Mixed Bag for Investors Zydus Lifesciences Ltd. recently announced its Q2 FY26 results, which were a mixed bag for investors. While the company’s revenue beat estimates, its margins were subdued due to the lower revenue of gRevlimid and the impact of recent acquisitions in the consumer wellness and medtech divisions.

Harsha Engineers Shares Upgraded To ‘Buy’ By IDBI Capital: A Positive Outlook Harsha Engineers International Ltd. has delivered a strong set of Q2 results, prompting IDBI Capital to upgrade the stock to ‘Buy’ with a potential upside of 20%. The company’s revenue grew by 7% year-over-year (YoY), while Ebitda surged by 28% YoY to Rs

Introduction to the Indian and Chinese Markets The Indian and Chinese stock markets have been making headlines in recent times, with China experiencing a resurgence in its stock market, while India has been underperforming. According to Mark Matthews, Head of Research Asia at Julius Baer, these two markets are driven by different fundamentals and opportunities,

Indigo Paints Q2 Review: A Detailed Analysis Indigo Paints Ltd. has reported a strong Q2 performance, with revenue growth of 4.2% YoY, outperforming its key peers Kansai Nerolac, Berger Paints, and Akzo Nobel. The company’s Ebitda margin expansion of +106bps is also a notable achievement, especially when compared to the margin contractions seen by Berger

Lenskart IPO: Ambit Gives Sell Rating, Cites Valuation Concerns Lenskart, the popular eyewear retailer, is set to list on the Indian stock markets on Monday, but has already received its first sell rating from Ambit, a leading brokerage firm. The rating comes as a surprise, given Lenskart’s strong brand and growth prospects. However, Ambit believes

Hindalco Q2 Results: Strong Performance by India Business Drives 21% Profit Rise Aditya Birla Group’s metals arm Hindalco Industries Ltd has reported a 21.2% rise in consolidated profit after tax at Rs 4,741 crore in the quarter ended September 2025. This significant increase can be attributed to the strong performance by the India business, disciplined